## ZBH: Zimmer Biomet Holdings, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.94 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($85.74)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Zimmer Biomet will pay investors a cash dividend early next year**
- Source: Stock Titan | 20251217T120155 | Bullish | Relevance: 100%
- Zimmer Biomet (NYSE: ZBH) announced a quarterly cash dividend of $0.24 per share for the fourth quarter of 2025. The medical technology leader will pay the dividend on or about January 30, 2026, to shareholders of record as of December 30, 2025. This move reflects the company's strong financial position and ongoing commitment to returning value to its investors.

**2. Tag Archives: fourth quarter 2025**
- Source: InkFreeNews.com | 20251217T115200 | Bullish | Relevance: 100%
- Zimmer Biomet Holdings Inc. declared a quarterly cash dividend for the fourth quarter of 2025. This article from InkFreeNews.com discusses the dividend announcement.

**3. Zimmer Biomet partners with OneStep on mobility data for joint procedure recovery**
- Source: MassDevice | 20251216T142247 | Bullish | Relevance: 100%
- Zimmer Biomet announced an exclusive collaboration with OneStep to integrate OneStep's FDA-listed digital fall prevention and mobility intelligence platform into its offerings. This partnership aims to provide comprehensive mobility data for surgeons to track recovery effectively after joint replacement surgery and empower patients in their recovery journey. The OneStep data will be integrated into Zimmer Biomet's MyMobility care management platform for orthopedic surgery patients, providing objective insights and supporting personalized rehabilitation programs.

**4. Zimmer Biomet, OneStep Collaborate to Provide Enhanced Mobility Data to Patients and Surgeons to Help Improve Joint Procedure Recovery**
- Source: PR Newswire | 20251216T123208 | Bullish | Relevance: 100%
- Zimmer Biomet and OneStep have announced an exclusive collaboration to integrate OneStep's mobility intelligence technology into Zimmer Biomet's mymobilityÂ® Care Management Platform. This partnership aims to provide enhanced mobility data to patients and surgeons, improving recovery tracking and patient engagement following joint replacement surgery. The integration will allow users to access objective insights on their recovery using their smartphones, further strengthening Zimmer Biomet's connected care strategy.

**5. How To YieldBoost Zimmer Biomet Holdings From 1% To 11.7% Using Options**
- Source: Nasdaq | 20251217T164125 | Bullish | Relevance: 100%
- BNK Invest suggests a strategy for Zimmer Biomet Holdings (ZBH) shareholders to boost their income from 1% to 11.7% using options. By selling a September 2026 covered call at the $95 strike price, investors can collect a premium that annualizes to an additional 10.7% return. This strategy offers a total annualized return of 11.7% if the stock is not called away, or an 11.1% total return if it is called away after a 3.1% appreciation.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-16 | Baird | $100 | $117 | -15% |
| 2025-12-11 | Citigroup | $94 | $98 | -4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-16 | Baird | down | Neutral |
| 2025-12-11 | Citigroup | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 9 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (+0.2%)
- Dodge & Cox Inc.: 11.7% (+5.1%)
- Blackrock Inc.: 8.1% (+0.2%)
- Price (T.Rowe) Assoc: 7.6% (+1.9%)
- State Street Corpora: 4.4% (-1.3%)

### Key Risks

1. Long-term trend broken: trading 8.1% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.94 indicates undervaluation relative to growth. Forward P/E 10.6x stretched relative to 4% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $17.9B |
| Beta | 0.61 |
| 52W Range | $85.33 - $114.44 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.94 |
| Forward P/E | 10.6 |
| Current P/E | 11.1 |
| YoY Growth | 4.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.7% over 5 days). Below STRENGTH zone by 6.3pp (needs >4.0% for momentum thesis). AM_20 at -3.0% indicates price below own 20MA trend. Below SMA200 (0.92x), long-term trend not supportive. RSI neutral at 41. OFD pattern: -MUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.32% (CS: 19) | Weak |
| RSI_14 | 40.8 | Neutral |
| MACD Histogram | -0.14 | Bearish |
| vs SMA20 | 0.970x | Below |
| vs SMA50 | 0.951x | Below |
| vs SMA200 | 0.919x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $90.38
- **Stop Loss:** $85.74 (5.1% risk)
- **Target:** $99.66 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 204
- **Position Value:** $18,437.52
- **Portfolio %:** 18.44%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-05 (Est: $2.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.87 | $1.90 | +1.8% |
| 2025Q2 | $1.98 | $2.07 | +4.8% |
| 2025Q1 | $1.77 | $1.81 | +2.3% |
| 2024Q4 | $2.29 | $2.31 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*